Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Grass Pollen Allergy-Pipeline Review, H1 2015

Grass Pollen Allergy-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Grass Pollen Allergy-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Grass Pollen Allergy-Pipeline Review, H1 2015', provides an overview of the Grass Pollen Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Grass Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Grass Pollen Allergy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Grass Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Grass Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Grass Pollen Allergy Overview 7

Therapeutics Development 8

Pipeline Products for Grass Pollen Allergy-Overview 8

Pipeline Products for Grass Pollen Allergy-Comparative Analysis 9

Grass Pollen Allergy-Therapeutics under Development by Companies 10

Grass Pollen Allergy-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Grass Pollen Allergy-Products under Development by Companies 14

Grass Pollen Allergy-Companies Involved in Therapeutics Development 15

ALK-Abello A/S 15

Allergy Therapeutics plc 16

Anergis SA 17

Biomay AG 18

BioTech Tools s.a. 19

Circassia Pharmaceuticals plc 20

HAL Allergy BV 21

Laboratorios LETI S.L. 22

Roxall Medizin GmbH 23

Grass Pollen Allergy-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

AllerG-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Allergen Extract Of Phleum Pratense-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Avanz Phleum Pratense-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

BM-32-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

clustoid wiesenlieschgras-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

gpASIT + TM-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

grass allergy vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Grass-SPIRE-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Pollinex Quattro Grass-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

timothy grass pollen allergen extract-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Grass Pollen Allergy-Recent Pipeline Updates 46

Grass Pollen Allergy-Dormant Projects 50

Grass Pollen Allergy-Product Development Milestones 51

Featured News & Press Releases 51

Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 51

Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 51

Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 52

Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 53

Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 53

Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 54

Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 54

Dec 06, 2013: Ethical committee of the University of Leuven approves a follow-up of the Phase IIa clinical study BTT006 to confirm a 2 years lasting immunological impact of 5 injections of gp-ASIT+TM 55

Nov 18, 2013: Update on Biotech Tools Phase IIa clinical study in the grass pollen allergy therapy 55

Nov 09, 2013: Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

Number of Products under Development for Grass Pollen Allergy, H1 2015 8

Number of Products under Development for Grass Pollen Allergy-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Grass Pollen Allergy-Pipeline by ALK-Abello A/S, H1 2015 15

Grass Pollen Allergy-Pipeline by Allergy Therapeutics plc, H1 2015 16

Grass Pollen Allergy-Pipeline by Anergis SA, H1 2015 17

Grass Pollen Allergy-Pipeline by Biomay AG, H1 2015 18

Grass Pollen Allergy-Pipeline by BioTech Tools s.a., H1 2015 19

Grass Pollen Allergy-Pipeline by Circassia Pharmaceuticals plc, H1 2015 20

Grass Pollen Allergy-Pipeline by HAL Allergy BV, H1 2015 21

Grass Pollen Allergy-Pipeline by Laboratorios LETI S.L., H1 2015 22

Grass Pollen Allergy-Pipeline by Roxall Medizin GmbH, H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Assessment by Combination Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Route of Administration, H1 2015 28

Number of Products by Stage and Molecule Type, H1 2015 30

Grass Pollen Allergy Therapeutics-Recent Pipeline Updates, H1 2015 46

Grass Pollen Allergy-Dormant Projects, H1 2015 50

List of Figures

Number of Products under Development for Grass Pollen Allergy, H1 2015 8

Number of Products under Development for Grass Pollen Allergy-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Routes of Administration, H1 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28

Number of Products by Top 10 Molecule Types, H1 2015 29

Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ALK-Abello A/S

Allergy Therapeutics plc

Anergis SA

Biomay AG

BioTech Tools s.a.

Circassia Pharmaceuticals plc

HAL Allergy BV

Laboratorios LETI S.L.

Roxall Medizin GmbH

Grass Pollen Allergy Therapeutic Products under Development, Key Players in Grass Pollen Allergy Therapeutics, Grass Pollen Allergy Pipeline Overview, Grass Pollen Allergy Pipeline, Grass Pollen Allergy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com